CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

RegulatoryNeflamapimodPositive

AI Analysis

Summary

CervoMed announced that neflamapimod received Innovation Passport Designation under the UK Innovative Licensing and Access Pathway (ILAP) for the treatment of Dementia with Lewy Bodies, a regulatory milestone that facilitates expedited development and access.

Outcome Details

Awarded Innovation Passport Designation under UK Innovative Licensing and Access Pathway (ILAP)

Importance:6/10

Sentiment:

0.60

regulatory approvalUK ILAPInnovation PassportDLBneflamapimod

Related Companies

$CRVO

Read the original article

Published by yahoo_finance on August 4, 2026 9:15 AM

Read Original